These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25470147)

  • 1. Novel oral anticoagulants in non-valvular atrial fibrillation.
    da Silva RM
    Cardiovasc Hematol Agents Med Chem; 2014; 12(1):3-8. PubMed ID: 25470147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
    Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Update on current care guidelines: atrial fibrillation].
    Käypä hoito -suosituksen päivitystiivistelmä
    Duodecim; 2012; 128(4):374-6. PubMed ID: 22448550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation in atrial fibrillation.
    Steinberg BA; Piccini JP
    BMJ; 2014 Apr; 348():g2116. PubMed ID: 24733535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New anticoagulants in patients with atrial fibrillation].
    Diener HC; Weber R
    MMW Fortschr Med; 2013 May; 155(8):55-6, 58. PubMed ID: 24437140
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.